Taysha Gene Therapies (NASDAQ:TSHA) Releases Earnings Results, Beats Expectations By $0.03 EPS

Taysha Gene Therapies (NASDAQ:TSHA) issued its quarterly earnings data on Thursday. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.03, FiscalAI reports. The company had revenue of $5.49 million during the quarter, compared to analyst estimates of $1.89 million. Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%.

Taysha Gene Therapies Price Performance

TSHA stock opened at $4.45 on Thursday. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of -13.48 and a beta of 1.02. The firm’s 50-day moving average price is $4.66 and its two-hundred day moving average price is $4.53. The company has a current ratio of 10.48, a quick ratio of 10.48 and a debt-to-equity ratio of 0.23. Taysha Gene Therapies has a 12-month low of $1.05 and a 12-month high of $6.02.

Analyst Ratings Changes

Several research firms have recently weighed in on TSHA. Wells Fargo & Company raised their price objective on shares of Taysha Gene Therapies from $8.00 to $11.00 and gave the company an “overweight” rating in a research report on Monday, January 5th. The Goldman Sachs Group set a $11.00 target price on Taysha Gene Therapies in a research note on Thursday, December 4th. Raymond James Financial restated a “strong-buy” rating and set a $13.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, January 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Monday, December 29th. Finally, UBS Group set a $11.00 price objective on Taysha Gene Therapies in a report on Thursday, December 4th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $10.91.

Insider Buying and Selling

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 26,918 shares of the stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $4.61, for a total value of $124,091.98. Following the completion of the sale, the insider owned 1,317,389 shares in the company, valued at approximately $6,073,163.29. This trade represents a 2.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Sean P. Nolan sold 41,312 shares of the business’s stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $4.61, for a total value of $190,448.32. Following the transaction, the chief executive officer directly owned 2,908,257 shares in the company, valued at $13,407,064.77. This trade represents a 1.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 598,623 shares of company stock valued at $2,822,188 over the last ninety days. 3.78% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in TSHA. Legal & General Group Plc boosted its stake in shares of Taysha Gene Therapies by 25.8% during the 3rd quarter. Legal & General Group Plc now owns 23,149 shares of the company’s stock valued at $76,000 after purchasing an additional 4,754 shares in the last quarter. CIBC Bancorp USA Inc. purchased a new position in shares of Taysha Gene Therapies during the third quarter valued at about $74,000. CIBC Asset Management Inc bought a new position in Taysha Gene Therapies in the fourth quarter worth about $66,000. Panagora Asset Management Inc. purchased a new stake in Taysha Gene Therapies in the fourth quarter worth about $64,000. Finally, Guggenheim Capital LLC purchased a new stake in Taysha Gene Therapies in the fourth quarter worth about $61,000. 77.70% of the stock is owned by hedge funds and other institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.